Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer

Table 2 Clinical trials of neoadjuvant epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutated non-small-cell lung cancer

Clinical trial	Study type	Sample size	Primary outcome	Stage	Treatment	TKI duration	RR	R0 resectability rate	PR	OS
Zhong et al[60]	Phase II	24 (12 with EGFR mutation)	RR	IIIA	Erlotinib (patients with EGFR mutation) vs carboplatin-gemcitabine (patients with native EGFR)	42 d	58.3% vs 25%; P = 0.18	50% vs 71.4; P = 0.59	16.7% vs 25%; P = 0.64	14.5 vs 28.1 mo; P = 0.201
Xiong et al[61]	Phase II	25	Resectability rate	IIIA	Erlotinib	56 d	42.1%	68.4%	50%	51.6 mo
Xiong et al[62]	Phase II	31 (15 with EGFR mutation)	Resectability rate	IIIA	Erlotinib vs cisplatin-based chemotherapy	4-7 wk	67% vs 19%	80% vs 50%	67% vs 38%	51 vs 20.9 mo
EMERGING-CTONG 1103, Zhong et al[63], Wu et al[64]	Phase II	72	RR	IIIA	Erlotinib vs cisplatin-gemcitabine	42 d (12 mo after surgery)	54.1% vs 34.3%; P = 0.092	73% vs 63%	MPR: 9.7% vs 0%	42.2 vs 36.9 mo; HR: 0.83; P = 0.513

EGFR: Epidermal growth factor receptor; HR: Hazard ratio; MPR: Major pathological response; OS: Overall survival; PR: Pathological response; RR: Response rate; TKI: Tyrosine kinase inhibitor.